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Abstract
UK drug discovery and development is increasingly being shaped through a complex interaction of research, policy and
practice. However, our understanding of this innovation system is partially due to the dearth of systems-level empirical
studies and to simplistic conceptual approaches. This study uses a Triple Helix systems approach to illustrate how a novel
databaseof Research Excellence Framework 2014 impact case studies may be used both to advance empirical understanding of
UK drug discovery and development and for theory development. The authors refine the Triple Helix system by identifying
relationships between its three components (academia, government and industry) and various social actors. The paper also
make two contributions to practice, concerning the relative unimportance for impact generation of geographical clusters
relative to strategic alliances, network linkages and knowledge spillovers, and the strong bias towards national and Anglo-
American academic–practitioner linkages with few or no links to emerging knowledge economies.
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UK drug discovery and development is increasingly being
shaped through a complex interaction of research, policy
and practice, in response to technological advances and
changing demographic and socioeconomic trends (Corbett
et al., 2017; Deloitte, 2017; NHS England, 2017). Big
Pharma business models have largely shifted from vertical
integration to network or systems integration, emphasising
precompetitive initiatives and public–private partnerships
(Cooke, 2004; Hunter and Stephens, 2010; Pricewaterhou-
seCoopers, 2009; Ràfols et al., 2014; TBR and CBSL,
2016). The UK government has adopted increasingly sup-
portive policies, including smart specialisation strategies, the
Life Sciences Sector Deal and the Industry Strategy (BEIS,
2017; Bell, 2017; DBIS, 2015), and is encouraging academia
to engage in impact, defined as ‘an effect on, change or
benefit to the economy, society, culture, public policy or
services, health, the environment or quality of life, beyond
academia’ (HEFCE, 2011).
In order to design effective policy and business strate-
gies in this changing landscape, the division of innovative
labour (what actors are involved in innovation, their func-
tions and interactions) must be clearly understood to avoid
the hyping up of some and the neglect of others (Lazonick
and Mazzucato, 2013). However, the dearth of systems-
level empirical studies exploring UK drug discovery and
development means that our understanding of the system is
partial and likely to be anecdotal or ‘myth-laden’ (Corbett
et al., 2017; Hopkins et al., 2007; Light and Lexchin, 2012;
Munos, 2009; Scannell et al., 2012; Schmid and Smith,
2005). To illustrate, studies of impact-related innovation
focus on knowledge commercialisation and industry
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engagement at research-intensive higher education institu-
tions (HEIs), and typically neglect teaching-led HEIs, non-
profit organisations, government bodies and patient groups,
service and process innovation, and localised practice-
based innovations (Abreu et al., 2016; Barlow, 2017;
Caron-Flinterman et al., 2007; Dalziel, 2007; Hughes and
Kitson, 2012; Smith et al., 2015; Savory, 2009).
The inclusion of an impact assessment in the UK’s 2014
Research Excellence Framework (REF2014) constitutes the
first national-level systematic evaluation of academic
research not only according to academic outputs but also to
effects on society (Hinrichs-Krapels and Grant, 2016).
REF2014 has left a rich database of case studies submitted
by all UK HEIs describing the significance and reach of
impact underpinned by research during the period January
1993 to December 2013 (KCL and Digital Science, 2015),
how impact emerged and who was involved in its emergence.
It offers a new longitudinal perspective on the division of
innovative labour in a range of UK innovation systems.
In this paper, we illustrate how REF case studies may be
used both for theory development and as a means to under-
stand or advance insight into the UK drug discovery and
development system. We develop a three-stage review
approach to do this:
(1) Choosing a conceptual model with acceptable
explanatory power. We critically appraise concep-
tual models of how research, policy and practice
inform and interact with each other, and identify
the Triple Helix systems model (Ranga and Etzko-
witz, 2013) as being appropriate to explore impact
case studies.
(2) Systematic review of REF case studies. We employ
a systematic review methodology (Tranfield et al.,
2003) to interrogate the REF2014 database and
identify 268 case studies relevant to drug discovery
and development.
(3) Integrative synthesis. We adopt a systematic com-
bining approach (Dubois and Gadde, 2002) to
develop a Triple Helix systems perspective of
UK drug discovery and development.
Our work adds to existing research in three important
ways. First, our novel methodology constitutes the first
exploration of REF data within a particular context of
application rather than a field of research (Greenhalgh and
Fahy, 2015; Hole, 2017; Pidd and Broadbent, 2015), and
thereby offers a template for the exploration of subsequent
REF exercises. Second, we refine the Triple Helix system
by identifying relationships between its three components
(academia, government and industry) and social actors,
including non-governmental organisations (NGOs), the
media and supranational organisations. Third, we expand
empirical knowledge concerning how academics and aca-
demic research contribute to the UK drug discovery and
development system. We make two contributions to prac-
tice, concerning the relative unimportance of geographical
clusters relative to strategic alliances, network linkages and
knowledge spillovers, and the strong bias towards national
and Anglo-American academic–practitioner linkages with
few or no links to emerging knowledge economies.
Stage 1: Choosing a conceptual model with
acceptable explanatory power
Three broad approaches have been used to conceptualise
how impact is derived from research: linear, relational and
system models (Best and Holmes, 2010). Linear models
envisage a unidirectional flow of knowledge from basic
research to applied research to commercialisation (Hara,
2003). This type of model is problematic, and has been
described as a ‘folk model’ (Balconi et al., 2010) and a
‘classic straw man’ (Edgerton, 2004) never intended to be
an analytically useful concept. It is technologically deter-
ministic (neglecting market pull or societal need) and its
use has led to a disproportionate emphasis on scientific
research and a neglect of both the business processes
required to bring technology to the market (Balconi et al.,
2010; Edgerton, 2004; Tait and Williams, 1999) and the
role of industry (Vallas and Kleinman, 2008).
Relational models are more sophisticated and emphasise
knowledge sharing and the development of partnerships,
networks and clusters consisting of stakeholders with com-
mon interests. There is a large body of literature which
explores the factors that facilitate or impede relationships
between academia and industry (Ankrah and Al-Tabbaa,
2015; D’Este and Patel, 2007; Perkmann et al., 2013),
although other actors (local and national government, pub-
lic funding bodies, the third sector, and intermediary orga-
nisations) have received less attention. However, relational
models often neglect the fact that knowledge diffusion and
relationship forming are mediated by structures containing
actors with varying priorities, expectations, worldviews,
capabilities and vocabularies. As a consequence, systemic
factors that influence the development of impact from
research, such as institutional biases (Abraham, 2009;
Davis and Abraham, 2011) or societal concerns about the
accountability of scientific research (Stokols et al., 2008)
are generally ignored.
Systems models are the most sophisticated model cur-
rently available (Carlsson et al., 2002). These recognise
that innovation occurs in dynamic and constantly changing
complex adaptive systems, shaped by culture, structures,
priorities and the capacities of, and feedback between,
actors (Best et al., 2009). Various system types (national,
regional, sectoral, technological) have been studied, but
rarely in the context of UK drug discovery and develop-
ment. Using a combination of hand-searching Nature jour-
nals and a selective search of Web of Science, we found
just four papers relevant to the UK context, adopting
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national, regional and technological innovation systems
perspectives (Cooke, 2004; Herrmann and Peine, 2011;
Kooijman et al., 2017; Lawton Smith, 2004). The ‘ecosys-
tem’ approach, a concept based on the national system of
innovation, is beginning to be employed in the grey litera-
ture (Bell, 2017; Deloitte, 2017; HM Government, 2017;
TBR and CBSL, 2016). However, these examples rarely
explore impediments caused by the conflicting worldviews
or cultures of partners, and are therefore more likely under-
pinned by relationship models.
National, regional, technological and sectoral systems
approaches have been criticised on the grounds that many
accounts are overly descriptive, and that geographically or
sectorally delimited systems do not adequately account for
the increasingly open and globalised nature of research and
innovation (Weber and Truffer, 2017). Furthermore, they
position the industrial firm as the primary locus of techno-
logical innovation. As Big Pharma increasingly adopts the
role of network or systems integrator rather than innovation
locus, the explanatory power of these types of systems
approaches may become increasingly limited (Cooke,
2004; Ràfols et al., 2014). Based on these considerations,
we chose the Triple Helix systems (THS) model (Ranga
and Etzkowitz, 2013) as our conceptual foundation. The
THS is based on the broader Triple Helix approach, one
of the most developed conceptual and empirical accounts
of the changing nature of university–industry–government
relationships in knowledge economies (Etzkowitz, 2003,
2011). The Triple Helix approach positions academia as
the primary locus of innovative knowledge creation, and
is therefore consistent with the perspective offered by REF
case studies.
Stage 2: Systematic review of drug
discovery and development case studies
Our review of impact case studies was based on the sys-
tematic literature review methodology developed by
Denyer and Tranfield (2009). This consisted of five steps:
question formulation; locating studies; study selection/eva-
luation; analysis/synthesis; and reporting/using results.
Question formulation
The scope, research question, protocol and inclusion/exclu-
sion criteria were established in dialogue with a guidance
panel consisting of academics and pharmaceutical industry
practitioners under the auspices of the British Pharmacolo-
gical Society.
Locating studies
The REF2014 impact case study database was selected as it
represents the first national level systematic evaluation of
research impact globally (Hinrichs-Krapels and Grant,
2016). REF2014 was conducted by the Higher Education
Funding Council for England (HEFCE) on behalf of all UK
research funding councils. It assessed the quality of HEI
research published between January 2008 to December
2013, and both the significance and reach of impact under-
pinned by research during the period January 1993 to
December 2013 (KCL and Digital Science, 2015). A total
of 154 (out of 164 publicly funded) UK HEIs submitted
6,975 impact case studies for assessment, of which 6,679
have been made publicly accessible (HEFCE, 2014). These
are spread across four panels: life sciences, engineering and
physical sciences, social sciences, arts and humanities.
Case studies were not assessed for academic rigour dur-
ing the REF exercise and so may be considered an example
of grey literature – that is, ‘knowledge artefacts that are not
the product of peer-review processes characterising publi-
cation in scientific journals’ (Adams et al., 2017: 433). We
characterise REF2014 case studies as first-tier grey litera-
ture according to Adams’s taxonomy. This differentiates
along two dimensions: outlet control (the extent to which
content is produced, moderated or edited in conformance
with explicit and transparent knowledge creation criteria)
and source expertise (the extent to which the authority of
the producer of content can be determined). In terms of
outlet control, case studies have significant retrievability
in that they have been made available on a publicly acces-
sible website maintained by UK Research and Innovation
(UKRI). In terms of source expertise, case studies have
significant credibility in that they were written by or with
the involvement of academics who led research projects
which underpinned impact. In addition, impact claims in
case studies were required to be supported by evidence for
the purposes of REF2014, and there is evidence that legit-
imate claims were sometimes not made due to difficulties
in establishing proof (Manville et al., 2014). Thus we con-
sider relevant REF2014 case studies to offer credible
accounts from the perspective of focal academics of the
UK drug discovery and development THS.
Study selection/evaluation
Our search strategy (Figure 1) involved identifying case
studies in the REF2014 database relevant to a drug discov-
ery and development context. In consultation with our
mixed academic and practitioner guidance panel, we devel-
oped a list of keywords relevant to this context (Appendix
1). This method of drawing on the tacit knowledge of sta-
keholders was chosen in order to improve legitimacy and
validity of the ensuing synthesis (Dixon-Woods, 2011). We
combined these keywords into a number of search strings
and used these to search the REF database and extract
relevant case studies. In all, 3,645 case studies were
extracted in this way.
In order to reduce our pool of extracted case studies, we
adopted a fitness-for-purpose approach whereby quality
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appraisal was suborned to the relevance of the case studies
in contributing to synthesis and understanding of the
research problem (Briner et al., 2009; Pawson, 2006; Van
Aken and Romme, 2009). This was a two-stage process,
consisting of a coarse evaluation, based on a reading of the
‘Summary of impact’, followed by a fine evaluation,
based on a reading of the ‘Details of impact’. Thus no
study was excluded on the basis of quality, but rather
studies were included on the basis of relevance if the
relevant sections of the case study included at least one
of a list of inclusion criteria developed by the research
team (Table 1). Reliability was achieved by exceeding
an 80% agreement threshold among a research team con-
sisting of both academic and industry subject matter
experts. In this way, we reduced our pool to a shortlist
of 268 relevant case studies.
We defined the term ‘drug’ to mean medicine not
restricted to use in humans, and therefore include small
molecule drugs as well as other approaches (e.g. biologics,
stem cells). For the purposes of this categorisation we
included the reporting of new therapeutic avenues as a
result of fundamental research as well as significant mile-
stones in the drug development process. We also included
evidence of a stratified/personalised approach; that is, the
use of genetic/biomarker information or techniques to
inform the discovery of new drugs. We excluded medical
devices, advances in drug disposal and surgical
interventions.
Analysis/synthesis
Case studies are not generalisable to a population and are
typically unsuitable for statistical generalisation (Yin,
2009), although they may be employed in the exploration
of likely variables and the explanation of relationships
between them using deductive reasoning (Easton, 1995).
Case studies are regarded as suitable for two types of gen-
eralisation (Mantere and Ketokivi, 2013; Tsang, 2014; Yin,
2009). The first, analytic or theoretical generalisation,
involves generalisation to a theoretical proposition,
enabling theory building. The second, falsification,
involves the rejection of theoretical propositions based on
case evidence and the consequential refinement of existing
theory, for example changing its proposed relationships
among concepts or its boundary conditions.
In this paper, we chose the former because of the variety
of established theoretical approaches to research impact
discussed previously. Our aim was to refine the THS model
by studying it in the context of UK drug discovery and
development. We adopted a systematic combining
approach (Alvesson and Sköldberg, 1994; Dubois and
Gadde, 2002), involving a systematic and iterative process
of data analysis in which an emerging conceptual model is
developed and refined, based on recurrent themes and pat-
terns in the data. The final aim is to create a solid theore-
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Figure 1. Search strategy.
Table 1. Inclusion criteria.
No. Inclusion criteria
1 A new/improved drug/therapeutic approach is named
2 New technology/approach for use in drug discovery or
development
3 New therapeutic avenue from target validation or beyond
to support the drug discovery process
4 New venture, company, network or channel for drug
discovery and development
5 A personalised/stratified medicine approach to develop new
therapies
6 An outreach or engagement programme explaining drug
discovery and development to audiences outside the field
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strengthening the practical validation of the research by
making the results relevant for relevant organisations.
Our model was based on the THS (Ranga and Etzko-
witz, 2013), defined as a set of three elements and
embedded in three spaces, which we used as thematic cate-
gories (Table 2).
Using examples of impact listed in the REF2014 gui-
dance instructions for sub-panel reviewers (HEFCE, 2012)
as a set of a priori codes, we categorised impacts in the
sequential order in which they are recorded in case studies.
We then mapped these, as well as the actors cited in case
studies, onto the framework in order to develop a perspec-
tive of the system. Data were extracted to specially
designed spreadsheet pro-formas. We triangulated findings
by drawing on secondary data from external sources refer-
enced in case studies, specifically the institutional affilia-
tions of co-authors of underpinning research papers and
financial reports of academic spin-offs listed at Company
House.
Descriptive summary
We find REF2014 drug discovery and development case
studies to be skewed, variable and geographically
distributed.
Geographically distributed. Our finalised shortlist of 268 drug
discovery and development case studies was submitted by
63 of the 154 HEIs that took part in REF2014. All cate-
gories of UK universities were included in our shortlist,
with the civic universities contributing the greatest number
of case studies (88). Just less than half (46%) were sub-
mitted by institutions within the Oxford–Cambridge–Lon-
don Golden Triangle, the world’s third largest technology
cluster (Bell, 2017), while clusters in the Midlands, the
North of England and the Edinburgh–Glasgow corridor
were also well represented.
Variable. While case studies adhere to a common template,
they show a significant amount of variability in data
recorded. For example, research funding through Quality
Related (QR) funding from funding councils, equity
finance or the proceeds of technology sales are specified
rarely or with a low level of specificity, while peer-
reviewed funding received from UK research councils, the
EU and charities, and to a lesser extent industry, are spec-
ified in greater detail. Analysis of institutional affiliation of
underpinning research co-authors enables identification of
actors not identified in the case study itself. This reinforces
our view that deductive approaches to case study analysis
should be treated with caution.
Skewed. Building on recent work on research evaluation
(Hinrichs-Krapels and Grant, 2016), we assessed the
impacts claimed in case studies according to three cate-
gories: effectiveness, efficiency and equity. We employed
a definition of R&D effectiveness as the ‘ability of an R&D
system to produce outputs with certain intended and
desired qualities’ (for example, medical value to patients
or commercial value) (Paul et al., 2010: 204). We also
adopted Paul et al.’s (2010: 204) definition of R&D effi-
ciency as the ‘ability of an R&D system to translate inputs
(e.g. ideas, investments, effort) into defined outputs (e.g.
internal milestones that represent resolved uncertainty for a
given project or product launches)’. Finally, we defined
R&D equity as the ability of an R&D system to translate
inputs to produce outcomes among certain beneficiaries or
addressing specific health needs.
We found that impacts cited in case studies were skewed
towards R&D effectiveness and efficiency. Our shortlist
contained 135 case studies (50%) that described the dis-
covery or development of a drug or therapeutic approach
underpinned by academic research, including 176 named
small molecules and 69 biologics, the majority of which
were novel. As an indication of the degree of ‘newness’ of
these drugs, 14 were described as first-in-class, 1 was fast-
tracked by the US Food and Drug Administration (FDA)
and 1 was designated as a breakthrough therapy by the
FDA. Our shortlist also included 142 (53%) studies that
described the development of a technology which
improved the efficiency of a stage of the drug discovery
and development process. These included imaging or
Table 2. Thematic categories.
Category Definition
Elements Components The institutional spheres of university, industry and government, each with a wide array of
actors, among whom a distinction is made between: (a) individual and institutional




Technology transfer via market or non-market interactions, collaboration and conflict
moderation, collaborative leadership, substitution, and networking
Spaces Knowledge space Competencies of knowledge generation, diffusion and use of the Triple Helix components
Innovation space Competencies of the ‘multi-sphere’ (hybrid) organisations and entrepreneurial individuals
Consensus space Competences that bring together the THS components to engage in ‘blue-sky’ thinking, discuss
and evaluate proposals for advancement towards a knowledge-based regime
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formulation technologies, catalysts, databases, prediction
software and cognitive tests.
By contrast, consideration of R&D equity is relatively
rare. For example, employment creation is typically cited
by case studies in terms of number of jobs rather than where
these jobs are created, suggesting a gap in the assessment of
impact concerning inclusive growth (‘improvements in the
social and economic wellbeing of communities that have
structurally been denied access to resources, capabilities,
and opportunities’) (George et al., 2012: 661). By compar-
ing the number of jobs created by academic spin-offs (gath-
ered from case studies and financial returns) to a
geographical distribution of average worker earnings
(Inclusive Growth Commission, 2016), we found a com-
paratively minor contribution to employment in poorer
regions (Figure 2).
As another illustration, we explored innovation direc-
tionality (the congruence of innovative products/services
with a strategic set of collective priorities) (Weber and
Rohracher, 2012) by collating the diseases targeted in case
studies and categorising them using both the International
Statistical Classification of Diseases and Related Health
Problems (10th Revision) database and the World Health
Organisation’s sustainable development goals (SDGs)
(World Health Organization, 2015). SDGs are part of a
triple bottom line approach to human wellbeing, a conse-
quence of a view that current innovation systems drive
medical R&D priority setting in the direction of greatest
profit, but not of greatest need or of true medical benefit
(Mazzucato, 2016; Sachs, 2012; UNSG, 2016). We found a
preponderance of research directed towards non-
communicable diseases, and in particular neoplasms
(Figure 3). By contrast other SDGs, such as those relating
to infectious diseases, mental health and reproductive
health, appear to be underrepresented. Just 15 case studies
(6%) describe work targeting orphan diseases (rare diseases
affecting small populations). This is consistent with the
finding of significant misalignments between health burden
and R&D efforts at global and various national levels
(Ràfols and Yegros, 2017).
Stage 3: Integrative synthesis
Actors
Entrepreneurial academics. Entrepreneurial academics are
the focus of each REF case study. These are academics
who recognise that knowledge has simultaneous theoreti-
cal, practical and interdisciplinary implications (polyva-
lence) and who attend both to advancing academic
knowledge and exploiting its practical and commercial
value (Etzkowitz and Viale, 2010). Within the THS
model, all lead academics in our case studies are consid-
ered as entrepreneurial, as they both published academic
outputs and adopted a variety of styles to exploit knowl-
edge value. These included venturing to form a going
concern, venturing as a channel for private funding to
advance research goals, industry engagement via joint
research, contract research, consulting, sitting on advisory
boards, membership of research consortia or simply via
patent licencing.































Figure 2. Distribution of jobs created by academic spin-offs relative to the percentage of workers earning less than the living wage.
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R&D innovators. R&D innovators include teams or depart-
ments that are directly engaged in research activities lead-
ing to innovation. We assessed these by selecting a
convenience sample of 100 of our 268 case study shortlist,
and then determining in each case study the institutional
affiliation of co-authors of papers cited as underpinning
research (Steele, 2000). This method provided rigour and
consistency, as case studies varied considerably in the
degree to which collaborators were detailed. However, this
method does underestimate the frequency of academic–
industry collaborations in our case studies as these were
not always accompanied by co-authored papers. We found
that research activities were undertaken by five main
groups: HEI-based academics, clinical researchers, indus-
try research groups, public bodies and NGOs.
The predominant (n ¼ 227) form of collaboration in aca-
demia was intra-institutional, including both informal inter-
departmental collaboration and context-specific research
centres. This is in line with the finding that entrepreneurial
universities adopt hybrid forms involving both conventional
hierarchical organisation with network-like mechanisms to
encourage both internal and external engagement (Styhre and
Lind, 2010). Interdepartmental collaborations with other UK
HEIs are the next most common (n ¼ 167), followed by
collaboration with rest of the world (RoW) (n ¼ 151) and
European (n ¼ 122) HEIs. RoW collaborations are predomi-
nantly with US HEIs, while there are very few collaborations
with HEIs in emerging knowledge economies, such as China
(n¼ 1), Singapore (n¼ 1), South Korea (n¼ 3), Brazil (n¼ 1),
Russia (n¼ 2), Indonesia (n¼ 0) and India (n¼ 0). Despite the
fact that many developing nations are now strategically invest-
ing to develop world-class universities to lead the shift towards
knowledge economies, this had not translated into significant
transnational academic collaborations in drug discovery and
development up to 2013 (Altbach and Salmi, 2011; Salmi,
2009). This agrees with an earlier finding that global flows
of biotechnology technological knowledge have largely
bypassed developing countries (Buctuanon, 2001).
Clinical researchers represent the next most common
collaborative partner. Collaborations with UK hospitals
were the most common (n ¼ 163) and appeared to be of
two types – multi-centre clinical trials and smaller-scale
research collaborations, often with hospitals affiliated with
or local to the HEI and aimed at addressing local issues.
Collaborations with European (n ¼ 62) or RoW (n ¼ 62)
hospitals involved multi-centre clinical or field trials only.
Industry collaborations are the next most common type
found. The extant literature on inter-organisational rela-
tions holds that it is primarily knowledge-intensive firms
with sufficient absorptive capacity (the ability to recognise
the value of new external information, assimilate it and
apply it to commercial ends) that engage in collaborations
(Inauen and Schenker-Wicki, 2011). Consistent with this,
we found that collaborations occurred with five types of
firm. First, pharmaceutical and biotechnology multina-
tional corporations (MNCs) including GSK, Pfizer, Astra
Non-SDG, 6%
Infecous diseases, 8%
Injuries & violence, 1%
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Figure 3. Direction of innovation.
Note: n ¼ number of case studies.
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Zeneca and Novartis, undertook multiple collaborations in
diverse projects. These included MNCs based in the UK
(n ¼ 26), Europe (n ¼ 13) and the USA (n ¼ 26). Second,
multinational technology suppliers, including 3M, Phillips,
Syngenta and Waters, predominantly undertook collabora-
tions in single case studies. These included MNCs based in
the UK (n¼ 8), Europe (n¼ 2) and the USA (n¼ 1). Third,
new technology-based firms (NTBFs, independent firms
less than 25 years old and active in high-technology indus-
tries) (Grilli and Murtinu, 2014) undertook single project
collaborations specifically related to their technologies.
These included ‘born global’ NTBFs (Oviatt and McDou-
gall, 1994), based in Europe (n ¼ 4) and the USA (n ¼ 11)
which sourced knowledge internationally, as well as UK-
based NTBFs (n ¼ 10). Fourth, university spin-offs
founded by the focal academics of case studies (n ¼ 25)
maintained collaborative links with their home HEIs.
Finally, a small number of collaborations with contract
research organisations (CROs, a ‘paradigm of private sci-
ence’ engaged in outsourced testing, in-house basic
research and cross-firm alliances (Mirowski and Van Horn,
2005: 507)) based in the UK (n ¼ 5), Europe (n ¼ 1), the
USA (n ¼ 6) and Canada (n ¼ 1) were noted.
Public bodies constituted the fourth most common R&D
innovators. In the UK, these included public research insti-
tutions such as National Institute of Health Research
(NIHR), Medical Research Council and Science, Technol-
ogy & Facilities Council laboratories (n¼ 13), governmen-
tal departments (n ¼ 2), governmental regulators such as
National Institute of Biological Standards & Controls (n ¼
6) and public health institutions, such as the Blood Service
(n ¼ 5). In Europe (n ¼ 29) and the RoW (n ¼ 43), only
public research and health institutions collaborated.
Finally, NGOs constitute the final R&D innovator we
observed (UK n¼ 16, Europe n¼ 12, RoW n¼ 14). These
were predominantly charitable research institutes, such as
Cancer Research UK (n ¼ 6), the Wellcome Trust (n ¼ 2),
Max Planck institutes (n ¼ 4), the Babraham Institute (n ¼
2) and WiCell (n ¼ 4). The only international NGO we
encountered as co-cited author was the World Health Orga-
nisation (WHO, n ¼ 2).
Non-R&D innovators. Non-R&D innovators include teams or
departments whose function is not R&D and yet engage in
innovation. In industry (e.g. production, sales, marketing,
design, procurement, finance functions), these have been
referred to as ‘neglected innovators’ and are often not sup-
ported by innovation policy (Hervas-Oliver et al., 2011).
More broadly, non-R&D innovation may also be present in
technology transfer, incubation activities, financing, cre-
ation and change of organisations. In our case studies, we
identified two types of non-R&D innovator, although nei-
ther is common. First, there are clinicians who engage with
focal academics in localised practice-based innovations.
Such innovations are routinely neglected in studies
concerning the UK’s National Health Service (NHS),
which emphasise innovation outcomes from formal
research projects (Savory, 2009). The second group com-
prises distribution companies who sign agreements with
academics or spin-offs to sell and distribute new
technologies.
Multi-sphere institutions. Multi-sphere institutions, or
hybrids, operate at the intersection of the university, indus-
try and government institutional spheres and synthesise
elements of each sphere in their institutional design (Batti-
lana and Lee, 2014). They encourage ‘boundary permeabil-
ity’, or ease of movement across institutional boundaries, to
improve effectiveness (Etzkowitz, 2012). They tend to
have hierarchies with few levels and less centralised deci-
sion making to encourage flexibility and responsiveness.
We identified five types: HEI supporting structures (tech-
nology transfer offices, seed capital providers), government
or EU public funding organisations, academic spin-offs,
venture capital firms/angel investors and non-profit
organisations.
Technology transfer offices act as brokers between
industry and academia, particularly in patent licensing and
allocation to academic ventures (Winch and Courtney,
2007). However, no business development role is claimed
for them in case studies, despite this being identified as
critical to knowledge diffusion (McAdam and Marlow,
2008). More broadly, HEIs occasionally acted to provide
early seed funding for academic ventures (e.g. Sheffield’s
Fusion IP, Warwick Ventures, Imperial Innovations, the
White Rose Seedcorn Fund).
Public funding bodies act as hybrids by unifying the
institutional spheres of government and academia.
Research Councils provide funding to support research
excellence based on peer review but also knowledge trans-
fer to generate economic growth, competitiveness, prosper-
ity and wellbeing (e.g. Higher Education Innovation
Funding) (HM Treasury et al., 2014). UK regional and
devolved governments provide seed funding (e.g. the Scot-
tish Co-Investment Fund, the North West Fund for Biome-
dical, Invest Northern Ireland) for the purposes of regional
development and, while instances of this were isolated, the
2017 UK Industrial Strategy includes a greater emphasis on
regional development (BEIS, 2017). Other UK public fund-
ing organisations we consider to be hybrids include the
NIHR and Public Health England. The US National Insti-
tutes of Health constitutes the only foreign source of public
funding for UK drug research of any consistency, while
single examples of funding by the Irish and Swedish gov-
ernments were identified.
Academic spin-offs, of which we identified 96, acted as
multi-sphere institutions by channelling private finance to
support research and tacit knowledge and technology from
academia to industry to produce commercialisable innova-
tion. Based on annual returns held by Companies House,
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these displayed a high degree of resilience, with just 11
ceasing trading up to 2017. Academic spin-offs appeared
to be of two types, those intended to operate as going con-
cerns and those founded with the intention that they would
be acquired at some point. They included contract research
organisations, firms with in-house drug discovery pro-
grammes and technology providers. Of the 96 spin-offs
we identified, 56 had remained operational by 2017, while
29 had been acquired or had merged. Three could be
regarded as scale-ups (average annualised growth in profit
or loss greater than 20 per cent per annum over a 3 year
period, and with more than 10 employees at the beginning
of the observation period) (Coutu, 2014). This finding is
consistent with the low representation of life sciences com-
panies (3) in the top 50 UK fast-growth science-based com-
panies (Royal Society, 2014). This suggests that there may
be impediments to scale-up in the life sciences sector that
are not experienced elsewhere.
Venture capital firms and angel investors linked aca-
demic entrepreneurs and markets by being the primary
funding source of spin-offs after seed rounds (Wright
et al., 2006). These mainly consisted of independent VC
firms. We also identified instances of corporate venture
capital via MNC subsidiaries.
Non-profit organisations may also be considered an
example of multi-sphere institutions, linking academia to
specific social needs which may not always overlap with
political or industrial needs (Smith et al., 2011). We iden-
tified a diverse landscape of charities in our case studies,
including large medical research charities (the Wellcome
Trust, Cancer Research UK, the British Heart Foundation),
small disease-specific charities (e.g. Lupus UK, the Alzhei-
mer’s Disease Society, the Migraine Trust) and a small
number of non-UK-based charities (e.g. the Bill and
Melinda Gates Foundation, the Croucher Foundation Hong
Kong, the Leukemia & Lymphoma Society). We also iden-
tified cases of the emergence of new non-profits via venture
philanthropy (ReverseRett) and academic social entrepre-
neurship (Kidscan, Lhasa Ltd). The roles of non-profits in
innovation systems have been largely neglected in aca-
demic research, although Canadian non-profits were found
to act as both institutional enablers or institutional bal-
ancers, increasing or decreasing respectively a firm’s abil-
ity to innovate by shaping the networks and markets in
which it participates (Dalziel, 2007). We found evidence
only for an enabling role in our case studies, and identified
four mechanisms by which it is undertaken within the drug
discovery and development THS: provision of research
funding through peer-reviewed grants, co-opting aca-
demics onto regulatory or governmental work groups, issu-
ing of clinical treatment guidelines, and advocacy on behalf
of a patient group. This is not to say that a balancing (or
another as yet unidentified) role is not in operation, but that
further research would be necessary to identify it.
Innovation organisers. Innovation organisers are institutions
or persons occupying a key institutional position and coor-
dinating a mix of top-down and bottom-up processes and
innovation stakeholders from different organisational back-
grounds to promote economic and social development and
ensure agreement and support for its realisation. We iden-
tified four such actors in our case studies. The EU provided
funding, networking support and strategic direction for
drug discovery and innovation to foster research excel-
lence, economic growth, regional development and social
cohesion via transnational collaboration (Maassen and
Stensaker, 2011). The predominant EU vehicles identified
in case studies were the Framework Programmes for
Research and Technological Development and the Innova-
tive Medicines Initiative, while other programmes were
also represented (PEACE II: ALFA; the European and
Developing Countries Clinical Trials Partnership). The
WHO provided research funding, administered procure-
ment programmes and treatment guidelines, and fostered
consensus-building to adjust national policies in areas
including malaria, trauma, polio and neglected tropical dis-
eases. The UK central government has traditionally
adhered to a laissez-faire approach, funding academic
research to secure societal benefits but ceding authority
with regard to work allocation to the academic community
under the Haldane principle (Hughes, 2011; Olssen and
Peters, 2005). However, our case studies do show isolated
examples of more supportive and directive interventions
(Enright, 2001), including the setting of strategic direction
for innovation and the establishment of funding mechan-
isms to support innovation. Finally, pharma and biotech
MNCs acted as innovation organisers by funding research,
coordinating clinical trials and bringing innovative treat-
ments to market.
Civil society. While the Triple Helix approach has been
instrumental in exploring the changing relations between
academia, industry and government, it nonetheless main-
tains the notion of a ‘protected space’ for academia from
society (Flink and Kaldewey, 2018), and therefore envi-
sages no active role for society within the innovation sys-
tem. However, as contextual knowledge becomes more
important, it is argued that society’s role can no longer
be neglected (Delanty, 1998). For example, patient partic-
ipation (‘patient involvement in decision-making in advi-
sory boards or committees at macro and meso levels of
health care, but also [ . . . ] involvement at micro level in
relation to decision-making on their own care and treat-
ment’) (World Health Organization, 2013: 8) has been
identified by the WHO as a high priority. In our case stud-
ies we identified three societal actors: NGOs (discussed
above), the media and patient groups. The media’s role
as described in case studies was invariably passive, report-
ing innovative developments in healthcare. However, we
did identify two mechanisms by which patient groups
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actively influence the innovation system, in addition to
simply receiving a new drug. The first, at a meso level, is
the previously-mentioned case of a parent of a child with
Rett syndrome who engaged in venture philanthropy to
fund research once reversibility was established. The sec-
ond, at a macro level, is the political advocacy role patient
groups played in securing regulatory approval and access to
certain treatments.
Relationships among components
Technology transfer. Technology transfer was the core activ-
ity taking place between entrepreneurial academics, R&D
and non-R&D innovators, innovation organisers and aca-
demic spin-offs within the knowledge space of the system.
This was achieved through five main channels: knowledge
commercialisation, academic engagement with non-
academic organisations, knowledge spillovers, graduate
and researcher mobility, and contributions to standards or
guidelines.
Knowledge commercialisation, including patent alloca-
tion and licensing, academic venturing, merger and acqui-
sition and joint venturing, has been widely explored in the
literature, although it is often over-emphasised in policy
discourse (Hughes, 2011). Patent allocation from HEIs to
spin-offs and licensing to external firms were common in
case studies. The acquisition of a spin-off or an R&D pro-
gramme, or subsequent mergers or acquisitions of firms
without direct involvement of the focal academic, were
also regularly identified. Isolated examples of joint ven-
tures involving a spin-off and an MNC or two MNCs were
observed.
Academic engagement with non-academic organisa-
tions has more recently emerged as a topic for attention
in the literature (Perkmann et al., 2013). There are various
types, including collaborative research, contract research,
co-authoring, co-patenting, consulting, secondment, infor-
mal advice, participation in work groups and advising par-
liamentary sub-committees. Previous research has argued
that such relational forms of involvement are seen as more
relevant by firms than by non-relational forms (patenting
and licensing) (Perkmann et al., 2011). This is consistent
with our findings for all types of R&D innovators and for
non-R&D innovator clinicians. However, non-R&D inno-
vator distribution firms engaged only in patent licensing.
We also found that relational activities were generally ini-
tiated by the firm in the case of pharmaceutical and biolo-
gical drugs, but often by the academic for other
technologies, indicating significant differences in open
innovation strategies and capabilities within these seg-
ments (Fontana et al., 2006).
Knowledge spillovers are non-market-based interac-
tions in which firms benefit from publicly-accessible
research findings rather than through their own R&D
(Davies, 2008; Nelson, 2009). In our case studies we
identified a number of instances of firms undertaking their
own research programmes once a new therapeutic avenue
or proof of concept had been established by the focal aca-
demic, generating R&D investment and employment
(though both are difficult to measure) as well as new drug
candidates.
Graduate and researcher mobility include the employ-
ment of an academic or student by a firm, and is regarded as
a channel by which tacit knowledge moves to industry
(Wright et al., 2008). Instances of academics leaving HEIs
to take up full-time employment were rare in our case
studies, but joint appointments (retaining an academic posi-
tion while taking up a strategic advisory position in an
MNC or a board appointment in a spin-off) were relatively
common. Graduate mobility was more common, though
was not often emphasised.
Finally, contributing to standards or guidelines was a
common method by which technology was transferred both
to the clinic and transnationally. This was usually under the
auspices of an NGO or regulatory agency. We are aware of
no research concerning this channel of technology transfer
in the literature.
Substitution. Substitution arises when a gap introduced by a
weakness in one institutional sphere is filled by another
sphere. A known example is the gap between public or
charitable research funding and venture capital funding
experienced by academic ventures (Nightingale et al.,
2009). We found examples of where HEI, regional/
devolved government (including regional development
authorities), central government and non-profit seed fund-
ing programmes had emerged to mitigate this. We also
identified isolated instances of other activities that we
regard as substitutions. The first was the founding of cha-
rities either by academics or patient groups to fund research
for a particular cause not already served by existing cha-
rities (Kidscan, ReverseRett, Lhasa Ltd). The second was
the involvement of corporate venture capital (CVC) in a
number of case studies. CVC has emerged relatively
recently, designed to overcome inefficiencies in the life
sciences ecosystem (Greene et al., 2010). The third was a
single case of an academic research group acting as the de
facto research group of a firm (Funxional Therapeutics
Ltd).
Networking. Networking between entrepreneurial aca-
demics, R&D innovators and multi-sphere institutions can
occur in both formal and informal structures and at sub-
regional, regional, national and international levels. We
found that these networks tended to be of two types in our
case studies. Within the knowledge space, networks (e.g.
the Centre for Applied Pharmacokinetic Research; the Sim-
cyp Consortium; the Bioconversion–Chemistry–Engineer-
ing Interface Programme; Lhasa; Division of Transduction
Therapy; Neuroallianz), are directly concerned with pre-
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competitive applied research and innovation. EU Frame-
work Programmes generally involve the establishment of
networks of this type. Within the consensus space, net-
works (e.g. the Structural Genomics Consortium; the
Human Toxicology Project Consortium; the Wellcome
Trust Case Control Consortium; the Tay-Sachs Gene Ther-
apy Consortium) engage in basic or user-inspired basic
research and ‘blue-sky’ thinking to guide advancement in
a specific field or context. A second type of consensus
space network is that which is led by patient groups and
emerges for the purpose of political advocacy. A third type,
innovation space networks, are known to exist although are
not discussed in our case studies.
Collaborative leadership. Collaborative leadership is under-
taken by innovation organisers to connect people from
different sectors and institutional spheres, to bridge gaps,
generate consensus and balance conflicts of interest. They
can integrate skills and enable people to develop compe-
tencies according to specific challenges, foster changes in
thinking and practical implementation, and create new
opportunities for knowledge exchange. The EU under-
takes collaborative leadership largely through public–pri-
vate partnerships within the Framework Programmes. The
WHO does so through research, procurement and advo-
cacy programmes designed to tackle specific social chal-
lenges. The UK central government plays a less
interventionist role, limited to setting strategic innovation
direction and establishing funding mechanisms. Pharma
and biotech MNCs collaboratively lead in large-scale
clinical trials.
Discussion
In this discussion, we illustrate how REF case studies may
be used both for theory development and as a means to
understand or advance insight into the UK drug discovery
and development system.
Refinement of the Triple Helix system model
Our first contribution is a refinement of the THS model
through a change in proposed relationships between con-
cepts (Table 3). The THS groups actors within three main
components: academia, industry and government. The
roles of other actors in the system, such as non-profit orga-
nisations, the media, patient groups, supranational organi-
sations and actors based in other countries are not well
developed or are neglected (Petruzzelli et al., 2010). Our
refinement aims to address this weakness and is based on
the Quadruple Helix approach (Carayannis and Campbell,
2012), a development of the Triple Helix. This sees eco-
nomic, political and knowledge systems interacting to form
an innovation system (Carayannis and Rakhmatullin,
2014).
Our refinement consists of the identification of civil
society and trans- and supranational actors and the mechan-
isms by which they influence the Quadruple Helix, based
on our empirical findings. Patients’ groups engage in sub-
stitution through venture philanthropy, and networking for
the purposes of political advocacy. NGOs engage directly
in technology transfer via co-authorships and the establish-
ment of guidelines and workgroups, and indirectly through
research funding and providing seed capital in the
Table 3. Triple Helix system of UK drug discovery and development.
System Component Relationship
Knowledge Entrepreneurial academics
R&D innovators (intra-/inter-institutional collaborations,




Political Innovation organisers (UK Government, EU, WHO)
R&D innovators (public health authorities)
Non-R&D innovators (devolved governments, regional
authorities, other national governments)
Collaborative leadership, technology
transfer, substitution, networking
Economic Innovation organisers (pharma/biotech MNCs)
R&D innovators (pharma/biotech MNCs, technology supplier






Public bodies (e.g. NICE, NIHR, NIH, research councils)
Regulatory agencies
Regional/devolved government seed capital providers
Collaborative leadership, networking
Society Patients’ groups Substitution, networking
NGOs Technology transfer, networking,
substitution
Supranational organisations (EU, WHO) Collaborative leadership, technology
transfer
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knowledge system. They also engage in networking for
political advocacy, and substitution to address gaps in pub-
lic or private research funding. While the media features
prominently in case studies, no claims are made for its
influence on any actor and its role appears limited to report-
ing innovative developments. We find no evidence of other
mechanisms of influence by civil society actors, such as
crowd funding or citizen science. Supranational organisa-
tions (the EU and WHO) engage in collaborative leadership
and technology transfer (establishing research, procure-
ment and advocacy programmes designed to tackle specific
social challenges) and networking, particularly in the
knowledge space.
Understanding the changing landscape of UK drug
discovery and development
Our second and third contributions are to practice and con-
cern advances in insight into the UK drug discovery and
development system. The first of these concerns geogra-
phical clusters (geographically proximate groups of inter-
connected companies, suppliers, service providers and
associated institutions in a particular field, linked by com-
monalities and complementarities) (Porter, 2003). Cluster-
ing is generally believed to enhance firm performance
through pooling of human capital, proximity to non-
traded inputs and specialised goods, easy access to markets
and reduced cost associated with knowledge spillovers
(Audretsch and Dohse, 2007; Audretsch and Lehmann,
2006). However, the role of geographical proximity in
knowledge spillovers from universities is problematic and
its importance is likely to be overstated (Davies, 2008).
While facilitating knowledge transfer, geographical prox-
imity is neither a necessary nor a sufficient condition for it
to take place and indeed may have a negative impact due to
technological lock-in (Boschma, 2005).
Based on an analysis of co-citation data of underpinning
research and on impact case studies themselves, we found
that strategic alliances, network linkages and knowledge
spillovers appeared to be much more important for impact
generation than geographical clusters (Zaheer and George,
2004). Indeed, geographical proximity was significant only
in interactions between an academic’s HEI and a university
spin-off, and between an academic’s HEI and a research
hospital. This is significant because both UK policy and
Big Pharma strategies have favoured geographical cluster-
ing and co-location with research-intensive HEIs in recent
years (Abramovsky et al., 2007; Smith and Bagchi-Sen,
2006). Our finding suggests that, despite a strategic empha-
sis on co-location, firms must remain open to the wider
external environment, for example through strong search-
ing, screening and signalling processes (Fontana et al.,
2006).
Our final contribution concerns transnational academic
capitalism, defined as the ‘integration of [a] transnational
dimension into teaching, research and service in a way that
enhances transnational integration between universities and
globalizing knowledge capitalism, and increases aca-
demics’ and universities’ possibilities to diversify their
external funding sources transnationally’ (Kauppinen,
2012: 544). We note a strong national and Anglo-
American bias in linkages between practitioners and UK
academics, with few or no links to emerging knowledge
economies such as China, Singapore, South Korea, Brazil,
Russia, Indonesia or India. It has been suggested elsewhere
that this is due to cultural and linguistic preferences and
geographical constraints imposed by person-embodied
exchanges and transfers of tacit knowledge (Arundel and
Geuna, 2004; Patel and Pavitt, 2000). This suggests that
most firms engaging in collaboration, with the possible
exceptions of born-global NTBFs and MNCs, do not lever-
age academics’ cosmopolitan networks of colleagues
established through social patterns of collaboration, colle-
giality and competition (Murray, 2004). If this is the case, it
suggests the need for an innovation organiser to encourage
link formation between UK academics and emerging
economies, similar to the EU’s role in UK–European SME
links and the WHO in UK–African links.
Conclusion
REF2014 case studies offer a new and important perspec-
tive on the UK’s innovation system, allowing the identifi-
cation of actors and longitudinal relationships within the
system. We have illustrated the utility of REF case studies
in this paper by developing a novel methodology to enable
the interrogation of case studies within a context of appli-
cation rather than a field of research. This has enabled us
both to make contributions in theory building through
refinement of the Triple Helix system and to advance
insight into UK drug discovery and development. Future
iterations of the REF, currently envisaged to be undertaken
in 2021, 2028 and beyond, offer the opportunity to under-
take longitudinal studies of the drug discovery and devel-
opment system as it doubtless undergoes further change
following the UK withdrawal from the EU and the contin-
ued policy efforts to position the UK as a global science
superpower that benefits every corner of the country.
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Appendix 1




Efficacy, biodistribution, pharmacokinetics, toxicity, drug discovery, biomarker, pharmacology, target,
receptor, binding, ligand, allosteric, bioavailable/biaovailability, metabolism, screening, high throughput,
clearance, cytochrome P450, hERG, diagnostic, in vivo, Phase 1/phase 2/phase 3, preclinical, experimental
medicine, pharmacophore, toxicophore, translational, immunology, microbiology, virology, biochemistry,
pharmacy, biomedical, prescribing, Drug development, Therapeutic dose, clinical trials, drug, therapeutic
efficacy, therapeutic exposure, safety margin, drug formulation, pharmacodynamics, duration of action,
structure based drug design, lead optimisation, hit to lead, QT, cardiac safety, blood brain barrier, active
transport, regulatory toxicology, ligand binding, molecular modelling
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